The product, Crunch, doesn’t have any carrier or filler additives and is designed to resist washing away or straying from surgical sites, according to a July 19 news release.
“Our newly launched crunch contains cancellous bone fragments within the crunch to provide the osteoconductive scaffolding to promote new bone growth,” Ossifix CEO Mark Estrada said in the release. “Healthcare practitioners can choose to add fresh marrow aspirate or allograft from the patient to promote further osteogenesis.”
Ossifix is a subsidiary of Umbra Applied Technologies Group and is based in Austin.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.